Last reviewed · How we verify
Proteus Mirabilis Osteomyelitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Cefaprin · Bristol-Myers Squibb
- Tobi · Novartis
- Claforan · Sterimax
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Epocelin
- Rocephin · Generic (originally Roche)
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Proteus Mirabilis Osteomyelitis patent landscape — cliff calendar, originator estates, attackable patents
- Proteus Mirabilis Osteomyelitis treatment landscape brief
- Proteus Mirabilis Osteomyelitis treatment updates RSS
Frequently asked questions about Proteus Mirabilis Osteomyelitis
What drugs treat Proteus Mirabilis Osteomyelitis?
Tracked treatments include Ramycin, Cefaprin, Tobi, Claforan, Vantobra, Nebcin, Ceftriaxon, Epocelin.
What is the treatment for Proteus Mirabilis Osteomyelitis?
Standard treatment for Proteus Mirabilis Osteomyelitis includes Ramycin, Cefaprin, Tobi, Claforan, Vantobra. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Proteus Mirabilis Osteomyelitis patent cliff · Proteus Mirabilis Osteomyelitis CI report
- Treatment: Ramycin
- Treatment: Cefaprin · Bristol-Myers Squibb
- Treatment: Tobi · Novartis
- Treatment: Claforan · Sterimax
- Treatment: Vantobra · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing